-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Alpha Tau Medical, Lowers Price Target to $7

Benzinga·12/10/2025 19:15:44
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and lowers the price target from $8 to $7.